The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

Disclosed herein are methods for the production of mutant bacteriophages with altered host range. Additionally, disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

The present invention relates to a composition and method for inhibiting the growth of pathogens causing liver abscesses in bovines. The composition comprises of one or more broad host-range (polyvalent) bacteriophages capable of infecting and lysing or more Fusobacterium species and an acceptable carrier for delivering said composition to said bovine. The bacteriophages are isolated and characterized for infecting and inhibiting the growth of pathogens. Particularly, the composition is orally administered daily to bovines. Moreover, the present invention relates to the method for controlling and inhibiting the growth of pathogens causing liver abscesses in bovines comprising sampling of cattle rumen; preparation of phage pools; isolation of polyvalent F. necrophorum phages; quantification of Fusobacterium species level in cattle rumen; creation of a Fusobacterium strain library; and genome sequencing of Fusobacterium species.

A method of treating, reducing or preventing bacterial infection in a wound, the method comprising: applying a film on the wound, the film including a biodegradable polymer with bacteriophages dispersed therein, wherein the polymer is a poly (ester amide urea).

Provided herein are methods and compositions for killing a target bacterium. Also disclosed are engineered bacteriophages.

The present invention relates to a novel bacteriophage CJ25 (KCCM11463P) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic Escherichia coli (APEC) of birds by using the bacteriophage CJ25 (KCCM11463P) or the composition.

One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

Disclosed herein are novel synthetic bacteriophages and bacteriophage compositions, methods of production thereof, and therapeutic uses thereof.

Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Shigella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Shigella species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).